Expert Review of Clinical Immunology
Volume 20, 2024 - Issue 1
Drug Profile
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus
Noémie Gensousa Department of Internal Medicine and Clinical Immunology, CHU Bordeaux, Hôpital Saint-André, Bordeaux, France;b UMR/CNRS 5164, ImmunoConcEpT, CNRS, University of Bordeaux, Bordeaux, France
https://orcid.org/0000-0002-8428-616XView further author information
https://orcid.org/0000-0002-8428-616XView further author information, Estibaliz Lazarob UMR/CNRS 5164, ImmunoConcEpT, CNRS, University of Bordeaux, Bordeaux, France;c Department of Internal Medicine and Infectious Diseases, Centre National de Référence des Maladies Auto-immunes Systémiques Rares RESO, CHU Bordeaux, Hôpital Haut Leveque, Pessac, Francehttps://orcid.org/0000-0002-4206-7399View further author information
https://orcid.org/0000-0002-4206-7399View further author information, Patrick Blancob UMR/CNRS 5164, ImmunoConcEpT, CNRS, University of Bordeaux, Bordeaux, France;d Department of Immunology and Immunogenetics, CHU Bordeaux, Hôpital Pellegrin, Bordeaux, Francehttps://orcid.org/0000-0002-5374-3639View further author information
https://orcid.org/0000-0002-5374-3639View further author information & Christophe Richezb UMR/CNRS 5164, ImmunoConcEpT, CNRS, University of Bordeaux, Bordeaux, France;e Department of Rheumatology, Centre National de Référence des Maladies Auto-immunes Systémiques Rares RESO, CHU de Bordeaux, Hôpital Pellegrin, Bordeaux, FranceCorrespondence[email protected]
https://orcid.org/0000-0002-3029-8739View further author information
https://orcid.org/0000-0002-3029-8739View further author information